MNMD240621P6000
- 0.03
- 0.000.00%
Mind Medicine Newsroom
Express News | Cantor Fitzgerald Reiterates Overweight on Mind Medicine
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of
Express News | MindMed Reports Completion Of End-of-phase 2 Meeting With FDA; Says Reached Alignment On Phase 3 Development Strategy For MM120 In Generalized Anxiety Disorder
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?
Leerink Partners Maintains Mind Medicine(MNMD.US) With Buy Rating
Leerink Partners analyst Rudy Li maintains $Mind Medicine(MNMD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 36.8% and a total average return of 11.2% over the p
Baird Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $27
Baird analyst Joel Beatty maintains $Mind Medicine(MNMD.US)$ with a buy rating, and maintains the target price at $27.According to TipRanks data, the analyst has a success rate of 46.7% and a total av
Don't Freak Out. It Isn't the End of the Line for Psychedelic Medicines. -- Barrons.com
By Josh Nathan-Kazis Turn on, tune in, drop in value. A frigid reception for one novel psychedelic treatment by a Food and Drug Administration advisory committee doesn't spell doom for all psychedel
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outwe
Psychedelic Drug Stocks Plummet On FDA Advisers' Doubts About Ecstasy Candidate -- WSJ
By Liz Essley Whyte Stocks for companies developing psychedelic treatments fell Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA,
What's Going On With MindMed And Psychedelic Stocks?
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stre
Mind Medicine Price Target Maintained With a $22.00/Share by RBC Capital
Mind Medicine Price Target Maintained With a $22.00/Share by RBC Capital
Mind Medicine Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/05/2024 212.06% RBC Capital $22 → $22 Reiterates Outperform → Outperform 05/28/2024 282.98% Baird → $27
Mind Medicine Down Over 14%, on Pace for Largest Percent Decrease Since September 2022 -- Data Talk
Mind Medicine (MindMed), Inc. (MNMD) is currently at $7.09, down $1.16 or 14.06% --Would be lowest close since March 6, 2024, when it closed at $5.94 --On pace for largest percent decrease since Sep
RBC Recommends Buying MindMed Amid Psychedelic Stocks Sell-off
FDA advisory group refuses MDMA marketing authorization; psychedelic concept stocks slump.
The independent advisory group of the US FDA voted against the marketing authorization application for the psychiatric drug MDMA, causing a pre-market drop for the hallucinogenic drug developer.
Sector Update: Health Care Stocks Steady Premarket Wednesday
Health care stocks were steady premarket Wednesday with the Health Care Select Sector SPDR Fund (XLV) 0.3% higher and the iShares Biotechnology ETF (IBB) recently inactive. Vir Biotechnology (VIR) was
Express News | Shares of Psychedelics Companies Are Trading Lower After an FDA Panel, on Tuesday, Rejected the Approval of MDMA Therapy for People With PTSD
Mind Medicine Shares Fall After FDA Committee Votes Against Lykos Therapeutics' Psychedelic Drug
Mind Medicine's (MNMD) shares were down 9% in Wednesday's premarket activity, a day after advisers to the US Food and Drug Administration voted against Lykos Therapeutics' psychedelic drug. Lykos Ther
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 50 points on Wednesday.Shares of DouYu International Holdings Limited (NASDAQ:DOYU) fell in today's pre-market trading
Top Premarket Decliners
MicroAlgo (MLGO) shares slumped 29% Wednesday premarket, paring Tuesday's rally. Mind Medicine (MNMD) shares dropped 15%, adding to Tuesday's losses. Vast Renewables (VSTE) shares fell 12%, shaving ga